Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Nutraceuticals
  4. Volume 5, Issue 1
  5. Article
Volume 5, Issue 1
  • ISSN: 2665-9786
  • E-ISSN: 2665-9794

Abstract

Polycystic Ovarian Syndrome (PCOS) is a complex condition characterized by chronic ovulation issues and hyperandrogenism, affecting approximately 6% to 20% of women of reproductive age, depending on diagnostic criteria. Symptoms typically manifest during early adolescence, presenting as irregular menstrual cycles, anovulation, and acne. While some mechanisms underlying PCOS development have been identified, its precise etiology and pathophysiology remain elusive.

This article delves into the pathogenesis and management of PCOS by exploring relevant literature on PubMed. Various contributing factors to PCOS were meticulously examined, including epigenetics, environmental toxins, stress, diet, inflammation, oxidative stress, hyperandrogenism, insulin resistance, and obesity. This review examines the importance of herbal remedies in addressing Polycystic Ovarian Syndrome (PCOS), focusing on the chemical makeup, mode of action, and therapeutic uses of specific herbal medications targeting PCOS. However, despite this investigation, there remains a significant gap in completed clinical trials on repurposed drugs for PCOS, often with small sample sizes and inconclusive outcomes. Given the limited research in this area, further studies and carefully planned clinical trials are warranted to understand PCOS and its management better. Additionally, gaining deeper insights into PCOS could facilitate the development of novel drugs targeting newly discovered pathways, thereby improving treatment options for individuals affected by this syndrome.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnt/10.2174/0126659786282036240503112128
2024-05-23
2024-12-23

  • From This Site

    /content/journals/cnt/10.2174/0126659786282036240503112128
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. DeansR. Polycystic ovary syndrome in adolescence.Med. Sci.201971010110.3390/medsci7100101 31581747
     [Google Scholar]
  2. WitchelS.F. OberfieldS.E. PeñaA.S. Polycystic Ovary Syndrome: Pathophysiology, presentation, and treatment with emphasis on adolescent girls.J. Endocr. Soc.2019381545157310.1210/js.2019‑00078 31384717
     [Google Scholar]
  3. Polycystic Ovary Syndrome.Available online: https://www.womenshealth.gov/a-z-topics/polycystic-ovary-syndrome (accessed on 22 September 2021).
  4. BednarskaS. SiejkaA. The pathogenesis and treatment of polycystic ovary syndrome: What’s new?Adv. Clin. Exp. Med.201726235936710.17219/acem/59380 28791858
     [Google Scholar]
  5. GanieM. VasudevanV. WaniI. BabaM. ArifT. RashidA. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India.Indian J. Med. Res.2019150433334410.4103/ijmr.IJMR_1937_17 31823915
     [Google Scholar]
  6. GlueckC.J. GoldenbergN. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics.Metabolism20199210812010.1016/j.metabol.2018.11.002 30445140
     [Google Scholar]
  7. DamoneA.L. JohamA.E. LoxtonD. EarnestA. TeedeH.J. MoranL.J. Depression, anxiety and perceived stress in women with and without PCOS: a community-based study.Psychol. Med.20194991510152010.1017/S0033291718002076 30131078
     [Google Scholar]
  8. Escobar-MorrealeH.F. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.Nat. Rev. Endocrinol.201814527028410.1038/nrendo.2018.24 29569621
     [Google Scholar]
  9. Mohammad SadeghiH. AdeliI. MousaviT. DanialiM. NikfarS. AbdollahiM. Drug repurposing for the management of depression: Where Do We Stand Currently?Life202111877410.3390/life11080774 34440518
     [Google Scholar]
  10. Differential Diagnosis of PCOS.Available online: https://www.verywellhealth.com/what-is-the-differential-diagnosis-of-pcos2616642 (accessed on 6 December 2021).
  11. WitchelS.F. BurghardA.C. TaoR.H. OberfieldS.E. The diagnosis and treatment of PCOS in adolescents: An update.Curr. Opin. Pediatr.201931456256910.1097/MOP.0000000000000778 31299022
     [Google Scholar]
  12. Polycystic Ovary Syndrome (PCOS).Available online: https://www.mayoclinic.org/diseases-conditions/pcos/diagnosistreatment/drc-20353443(accessed on 6 December 2021).
  13. Diagnosis of Polycystic Ovary Syndrome.Available online: https://www.nhs.uk/conditions/polycystic-ovary-syndrome-pcos/diagnosis/(accessed on 22 September 2021).
  14. European Society of Human Reproduction and Embryology.International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.2018 Available online: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/(accessed on 22 September 2021).
    [Google Scholar]
  15. IlieI.R. GeorgescuC.E. Polycystic ovary syndrome-epigenetic mechanisms and aberrant MicroRNA.Adv. Clin. Chem.201571254510.1016/bs.acc.2015.06.001 26411410
     [Google Scholar]
  16. CasadesúsJ. Noyer-WeidnerM. Epigenetics.Brenner’s Encyclopedia of Genetics2nd ed; Maloy, S.; Hughes, K., Eds.; Academic Press: San Diego, CA, USA201350050310.1016/B978‑0‑12‑374984‑0.00480‑0
     [Google Scholar]
  17. SagvekarP. DadachanjiR. PatilK. MukherjeeS. Pathomechanisms of polycystic ovary syndrome: Multidimensional approaches.Front. Biosci. (Elite Ed.)2018103384422 29293465
     [Google Scholar]
  18. IbáñezL. OberfieldS.E. WitchelS. AuchusR.J. ChangR.J. CodnerE. DabadghaoP. DarendelilerF. ElbarbaryN.S. GambineriA. Garcia RudazC. HoegerK.M. López-BermejoA. OngK. PeñaA.S. ReinehrT. SantoroN. Tena-SempereM. TaoR. YildizB.O. AlkhayyatH. DeebA. JoelD. HorikawaR. de ZegherF. LeeP.A. An international consortium update: Pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence.Horm. Res. Paediatr.201788637139510.1159/000479371 29156452
     [Google Scholar]
  19. FenichelP. RougierC. HieronimusS. ChevalierN. Which origin for polycystic ovaries syndrome: Genetic, environmental or both?Ann. Endocrinol. (Paris)201778317618510.1016/j.ando.2017.04.024 28606381
     [Google Scholar]
  20. AbbottD.H. DumesicD.A. LevineJ.E. Hyperandrogenic origins of polycystic ovary syndrome implications for pathophysiology and therapy.Expert Rev. Endocrinol. Metab.201914213114310.1080/17446651.2019.1576522 30767580
     [Google Scholar]
  21. RutkowskaA.Z. Diamanti-KandarakisE. Polycystic ovary syndrome and environmental toxins.Fertil. Steril.2016106494895810.1016/j.fertnstert.2016.08.031 27559705
     [Google Scholar]
  22. QuF. WangF.F. YinR. DingG.L. El-princeM. GaoQ. ShiB.W. PanH.H. HuangY.T. JinM. LeungP.C.K. ShengJ.Z. HuangH.F. A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells.J. Mol. Med.201290891192310.1007/s00109‑012‑0881‑4 22349439
     [Google Scholar]
  23. LiY. ChenC. MaY. XiaoJ. LuoG. LiY. WuD. Multi-system reproductive metabolic disorder: Significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS).Life Sci.201922816717510.1016/j.lfs.2019.04.046 31029778
     [Google Scholar]
  24. RochaA.L. OliveiraF.R. AzevedoR.C. SilvaV.A. PeresT.M. CandidoA.L. GomesK.B. ReisF.M. Recent advances in the understanding and management of polycystic ovary syndrome.F1000 Res.2019856510.12688/f1000research.15318.1 31069057
     [Google Scholar]
  25. JonesL. ReganF. Endocrine Disrupting Chemicals. Encyclopedia of Analytical Science3rd ed; Worsfold, P.; Poole, C.; Townshend, A.; Miró, M., Eds.; Academic Press: Oxford, UK, 20193138
     [Google Scholar]
  26. MerkinS.S. PhyJ.L. SitesC.K. YangD. Environmental determinants of polycystic ovary syndrome.Fertil. Steril.20161061162410.1016/j.fertnstert.2016.05.011 27240194
     [Google Scholar]
  27. CalinaD. DoceaA. GolokhvastK. SifakisS. TsatsakisA. MakrigiannakisA. Management of endocrinopathies in pregnancy: A review of current evidence.Int. J. Environ. Res. Public Health201916578110.3390/ijerph16050781 30836653
     [Google Scholar]
  28. SobolewskiM. BarrettE. Polycystic ovary syndrome: do endocrine-disrupting chemicals play a role?Semin. Reprod. Med.201432316617610.1055/s‑0034‑1371088 24715511
     [Google Scholar]
  29. SoaveI. OcchialiT. AssorgiC. MarciR. CasertaD. Environmental toxin exposure in polycystic ovary syndrome women and possible ovarian neoplastic repercussion.Curr. Med. Res. Opin.202036469370310.1080/03007995.2020.1729108 32046531
     [Google Scholar]
  30. PaliouraE. Diamanti-KandarakisE. Polycystic ovary syndrome (PCOS) and endocrine disrupting chemicals (EDCs).Rev. Endocr. Metab. Disord.201516436537110.1007/s11154‑016‑9326‑7 26825073
     [Google Scholar]
  31. PaliouraE. Diamanti-KandarakisE. Industrial endocrine disruptors and polycystic ovary syndrome.J. Endocrinol. Invest.201336111105111110.1007/BF03346762 24445124
     [Google Scholar]
  32. WangJ. WuD. GuoH. LiM. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome.Life Sci.201923611694010.1016/j.lfs.2019.116940 31604107
     [Google Scholar]
  33. StefanakiC. PervanidouP. BoschieroD. ChrousosG.P. Chronic stress and body composition disorders: Implications for health and disease.Hormones2018171334310.1007/s42000‑018‑0023‑7 29858868
     [Google Scholar]
  34. Steegers-TheunissenR.P.M. WiegelR.E. JansenP.W. LavenJ.S.E. SinclairK.D. Polycystic ovary syndrome: A brain disorder characterized by eating problems originating during puberty and adolescence.Int. J. Mol. Sci.20202121821110.3390/ijms21218211 33153014
     [Google Scholar]
  35. YangS. YangC. PeiR. LiC. LiX. HuangX. WuS. LiuD. Investigation on the association of occupational stress with risk of polycystic ovary syndrome and mediating effects of HOMA-IR.Gynecol. Endocrinol.2018341196196410.1080/09513590.2018.1460340 30044172
     [Google Scholar]
  36. SzczukoM. KikutJ. SzczukoU. Szydłowska, I.; Nawrocka-Rutkowska, J.; Ziętek, M.; Verbanac, D.; Saso, L. Nutrition strategy and life style in polycystic ovary syndrome—narrative review.Nutrients2021137245210.3390/nu13072452 34371961
     [Google Scholar]
  37. FaghfooriZ. FazelianS. ShadnoushM. GoodarziR. Nutritional management in women with polycystic ovary syndrome: A review study.Diabetes Metab. Syndr.201711Suppl. 1S429S43210.1016/j.dsx.2017.03.030 28416368
     [Google Scholar]
  38. MuscogiuriG. AltieriB. de AngelisC. PalombaS. PivonelloR. ColaoA. OrioF. Shedding new light on female fertility: The role of vitamin D.Rev. Endocr. Metab. Disord.201718327328310.1007/s11154‑017‑9407‑2 28102491
     [Google Scholar]
  39. CiebieraM. EsfandyariS. SibliniH. PrinceL. ElkafasH. Wojtyła, C.; Al-Hendy, A.; Ali, M. Nutrition in gynecological diseases: Current perspectives.Nutrients2021134117810.3390/nu13041178 33918317
     [Google Scholar]
  40. GreenwoodE.A. HuddlestonH.G. Insulin resistance in polycystic ovary syndrome: Concept versus cutoff.Fertil. Steril.2019112582782810.1016/j.fertnstert.2019.08.100 31731944
     [Google Scholar]
  41. PetrakisD. VassilopoulouL. MamoulakisC. PsycharakisC. AnifantakiA. SifakisS. DoceaA. TsiaoussisJ. MakrigiannakisA. TsatsakisA. Endocrine disruptors leading to obesity and related diseases.Int. J. Environ. Res. Public Health20171410128210.3390/ijerph14101282 29064461
     [Google Scholar]
  42. ShangY. ZhouH. HuM. FengH. Effect of diet on insulin resistance in polycystic ovary syndrome.J. Clin. Endocrinol. Metab.2020105103346336010.1210/clinem/dgaa425 32621748
     [Google Scholar]
  43. DabadghaoP. Polycystic ovary syndrome in adolescents.Best Pract. Res. Clin. Endocrinol. Metab.201933310127210.1016/j.beem.2019.04.006 31027973
     [Google Scholar]
  44. RosenfieldR.L. EhrmannD.A. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited.Endocr. Rev.201637546752010.1210/er.2015‑1104 27459230
     [Google Scholar]
  45. RothenbergS.S. BeverleyR. BarnardE. Baradaran-ShorakaM. SanfilippoJ.S. Polycystic ovary syndrome in adolescents.Best Pract. Res. Clin. Obstet. Gynaecol.20184810311410.1016/j.bpobgyn.2017.08.008 28919160
     [Google Scholar]
  46. JeanesY.M. ReevesS. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: Diagnostic and methodological challenges.Nutr. Res. Rev.20173019710510.1017/S0954422416000287 28222828
     [Google Scholar]
  47. PolakK. CzyzykA. SimonciniT. MeczekalskiB. New markers of insulin resistance in polycystic ovary syndrome.J. Endocrinol. Invest.20174011810.1007/s40618‑016‑0523‑8 27473078
     [Google Scholar]
  48. ZhangC. HuJ. WangW. SunY. SunK. HMGB1-induced aberrant autophagy contributes to insulin resistance in granulosa cells in PCOS.FASEB J.20203479563957410.1096/fj.202000605RR 32469087
     [Google Scholar]
  49. HeF. LiY. Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: a review.J. Ovarian Res.20201317310.1186/s13048‑020‑00670‑3 32552864
     [Google Scholar]
  50. BannigidaD.M. NayakB.S. VijayaraghavanR. Insulin resistance and oxidative marker in women with PCOS.Arch. Physiol. Biochem.2020126218318610.1080/13813455.2018.1499120 30450993
     [Google Scholar]
  51. AveryP.J. JorgensenA. HambergA.K. WadeliusM. PirmohamedM. KamaliF. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.Clin. Pharmacol. Ther.201190570170610.1038/clpt.2011.186 22012312
     [Google Scholar]
  52. ZengX. XieY. LiuY. LongS. MoZ. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.Clin. Chim. Acta202050221422110.1016/j.cca.2019.11.003 31733195
     [Google Scholar]
  53. DoceaA.O. VassilopoulouL. FragouD. ArseneA.L. FengaC. KovatsiL. PetrakisD. RakitskiiV.N. NosyrevA.E. IzotovB.N. GolokhvastK.S. ZakharenkoA.M. VakisA. TsitsimpikouC. DrakoulisN. CYP polymorphisms and pathological conditions related to chronic exposure to organochlorine pesticides.Toxicol. Rep.2017433534110.1016/j.toxrep.2017.05.007 28959657
     [Google Scholar]
  54. CassarS. MissoM.L. HopkinsW.G. ShawC.S. TeedeH.J. SteptoN.K. Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies.Hum. Reprod.201631112619263110.1093/humrep/dew243 27907900
     [Google Scholar]
  55. CondorelliR.A. CalogeroA.E. Di MauroM. La VigneraS. PCOS and diabetes mellitus: From insulin resistance to altered beta pancreatic function, a link in evolution.Gynecol. Endocrinol.201733966566710.1080/09513590.2017.1342240 28644709
     [Google Scholar]
  56. LiznevaD. Gavrilova-JordanL. WalkerW. AzzizR. Androgen excess: Investigations and management.Best Pract. Res. Clin. Obstet. Gynaecol.2016379811810.1016/j.bpobgyn.2016.05.003 27387253
     [Google Scholar]
  57. MacutD. Bjekić-Macut, J.; Rahelić, D.; Doknić, M. Insulin and the polycystic ovary syndrome.Diabetes Res. Clin. Pract.201713016317010.1016/j.diabres.2017.06.011 28646699
     [Google Scholar]
  58. BaskindN.E. BalenA.H. Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome.Best Pract. Res. Clin. Obstet. Gynaecol.201637809710.1016/j.bpobgyn.2016.03.005 27137106
     [Google Scholar]
  59. Ianoşi, S.; Ianoşi, G.; Neagoe, D.; Ionescu, O.; Zlatian, O.; Docea, A.O.; Badiu, C.; Sifaki, M.; Tsoukalas, D.; Tsatsakis, A.M.; Spandidos, D.A.; Călina, D. Age-dependent endocrine disorders involved in the pathogenesis of refractory acne in women.Mol. Med. Rep.20161465501550610.3892/mmr.2016.5924 27840992
     [Google Scholar]
  60. MooreA.M. CampbellR.E. Polycystic ovary syndrome: Understanding the role of the brain.Front. Neuroendocrinol.20174611410.1016/j.yfrne.2017.05.002 28551304
     [Google Scholar]
  61. CoyleC. CampbellR.E. Pathological pulses in PCOS.Mol. Cell. Endocrinol.201949811056110.1016/j.mce.2019.110561 31461666
     [Google Scholar]
  62. RuddenklauA. CampbellR.E. Neuroendocrine impairments of polycystic ovary syndrome.Endocrinology2019160102230224210.1210/en.2019‑00428 31265059
     [Google Scholar]
  63. ZhuJ. ChenZ. FengW. LongS. MoZ.C. Sex hormone-binding globulin and polycystic ovary syndrome.Clin. Chim. Acta201949914214810.1016/j.cca.2019.09.010 31525346
     [Google Scholar]
  64. LiY. ZhengQ. SunD. CuiX. ChenS. BulbulA. LiuS. YanQ. Dehydroepiandrosterone stimulates inflammation and impairs ovarian functions of polycystic ovary syndrome.J. Cell. Physiol.201923457435744710.1002/jcp.27501 30580448
     [Google Scholar]
  65. Sanchez-GarridoM.A. Tena-SempereM. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.Mol. Metab.20203510093710.1016/j.molmet.2020.01.001 32244180
     [Google Scholar]
  66. LiuY. LiuH. LiZ. FanH. YanX. LiuX. XuanJ. FengD. WeiX. The release of peripheral immune inflammatory cytokines promote an inflammatory cascade in PCOS patients via altering the follicular microenvironment.Front. Immunol.20211268572410.3389/fimmu.2021.685724 34079559
     [Google Scholar]
  67. ZuoT. ZhuM. XuW. Roles of oxidative stress in polycystic ovary syndrome and cancers.Oxid. Med. Cell. Longev.2016201611410.1155/2016/8589318 26770659
     [Google Scholar]
  68. RudnickaE. SuchtaK. GrymowiczM. Calik-KsepkaA. SmolarczykK. DuszewskaA.M. SmolarczykR. MeczekalskiB. Chronic low grade inflammation in pathogenesis of PCOS.Int. J. Mol. Sci.2021227378910.3390/ijms22073789 33917519
     [Google Scholar]
  69. ShorakaeS. RanasinhaS. AbellS. LambertG. LambertE. de CourtenB. TeedeH. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS.Clin. Endocrinol.201889562863310.1111/cen.13808 29992612
     [Google Scholar]
  70. SteptoN.K. Moreno-AssoA. McIlvennaL.C. WaltersK.A. RodgersR.J. Molecular mechanisms of insulin resistance in polycystic ovary syndrome: Unraveling the conundrum in skeletal muscle?J. Clin. Endocrinol. Metab.2019104115372538110.1210/jc.2019‑00167 30938770
     [Google Scholar]
  71. ManciniA. BrunoC. VerganiE. d’AbateC. GiacchiE. SilvestriniA. Oxidative stress and low-grade inflammation in polycystic ovary syndrome: Controversies and new insights.Int. J. Mol. Sci.2021224166710.3390/ijms22041667 33562271
     [Google Scholar]
  72. MizgierM. Jarząbek-Bielecka, G.; Wendland, N.; Jodłowska-Siewert, E.; Nowicki, M.; Brożek, A.; Kędzia, W.; Formanowicz, D.; Opydo-Szymaczek, J. Relation between inflammation, oxidative stress, and macronutrient intakes in normal and excessive body weight adolescent girls with clinical features of polycystic ovary syndrome.Nutrients202113389610.3390/nu13030896 33801995
     [Google Scholar]
  73. ZhangR. LiuH. BaiH. ZhangY. LiuQ. GuanL. FanP. Oxidative stress status in Chinese women with different clinical phenotypes of polycystic ovary syndrome.Clin. Endocrinol.2017861889610.1111/cen.13171 27489079
     [Google Scholar]
  74. LiuY. YuZ. ZhaoS. ChengL. ManY. GaoX. ZhaoH. Oxidative stress markers in the follicular fluid of patients with polycystic ovary syndrome correlate with a decrease in embryo quality.J. Assist. Reprod. Genet.202138247147710.1007/s10815‑020‑02014‑y 33216309
     [Google Scholar]
  75. Di SegniC. SilvestriniA. FatoR. BergaminiC. GuidiF. RaimondoS. MeucciE. RomualdiD. ApaR. LanzoneA. ManciniA. Plasmatic and intracellular markers of oxidative stress in normal weight and obese patients with polycystic ovary syndrome.Exp. Clin. Endocrinol. Diabetes2017125850651310.1055/s‑0043‑111241 28675914
     [Google Scholar]
  76. LaiQ. XiangW. LiQ. ZhangH. LiY. ZhuG. XiongC. JinL. Oxidative stress in granulosa cells contributes to poor oocyte quality and IVF-ET outcomes in women with polycystic ovary syndrome.Front. Med.201812551852410.1007/s11684‑017‑0575‑y 29260383
     [Google Scholar]
  77. LuJ. WangZ. CaoJ. ChenY. DongY. A novel and compact review on the role of oxidative stress in female reproduction.Reprod. Biol. Endocrinol.20181618010.1186/s12958‑018‑0391‑5 30126412
     [Google Scholar]
  78. UyanikogluH. SabuncuT. DursunH. SezenH. AksoyN. Circulating levels of apoptotic markers and oxidative stress parameters in women with polycystic ovary syndrome: A case-controlled descriptive study.Biomarkers20172271510.1080/1354750X.2016.1265004 27899026
     [Google Scholar]
  79. ÖzerA. BakacakM. Kıran, H.; Ercan, Ö.; Köstü, B.; Kanat-Pektaş, M.; Kılınç, M.; Aslan, F. Increased oxidative stress is associated with insulin resistance and infertility in polycystic ovary syndrome.Ginekol. Pol.2016871173373810.5603/GP.2016.0079 27958630
     [Google Scholar]
  80. Guzmán HernándezE.A. Díaz PortilloS.A. Villafuerte AnayaÓ.C. González ValleM.D.R. Benítez FloresJ.D.C. ChávezR.S.M. GalindoG.C. MondragónL.D.V. CobosD.S. GuerreroG.A.M. Renoprotective and hepatoprotective effects of hippocratea excelsa on metabolic syndrome in fructose-fed rats.Farmacia20206861106111910.31925/farmacia.2020.6.19
     [Google Scholar]
  81. DelitalaA.P. CapobiancoG. DelitalaG. CherchiP.L. DessoleS. Polycystic ovary syndrome, adipose tissue and metabolic syndrome.Arch. Gynecol. Obstet.2017296340541910.1007/s00404‑017‑4429‑2 28643028
     [Google Scholar]
  82. WatanabeT. Watanabe-KominatoK. TakahashiY. KojimaM. WatanabeR. Adipose tissue-derived omentin-1 function and regulation.Compr. Physiol.20177376578110.1002/cphy.c160043 28640441
     [Google Scholar]
  83. DumesicD.A. AbbottD.H. SanchitaS. ChazenbalkG.D. Endocrine-metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective.Curr. Opin. Endocr. Metab. Res.202012414810.1016/j.coemr.2020.02.013 32363240
     [Google Scholar]
  84. SadeghiH.M. AdeliI. CalinaD. DoceaA.O. MousaviT. DanialiM. NikfarS. TsatsakisA. AbdollahiM. Polycystic ovary syndrome: A comprehensive review of pathogenesis, management, and drug repurposing.Int. J. Mol. Sci.202223258310.3390/ijms23020583 35054768
     [Google Scholar]
  85. LegroR.S. BarnhartH.X. SchlaffW.D. CarrB.R. DiamondM.P. CarsonS.A. SteinkampfM.P. CoutifarisC. McGovernP.G. CataldoN.A. GosmanG.G. NestlerJ.E. GiudiceL.C. LeppertP.C. MyersE.R. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.N. Engl. J. Med.2007356655156610.1056/NEJMoa063971 17287476
     [Google Scholar]
  86. ArmaniniD. CastelloR. ScaroniC. BonanniG. FacciniG. PellatiD. BertoldoA. FioreC. MoghettiP. Treatment of polycystic ovary syndrome with spironolactone plus licorice.Eur. J. Obstet. Gynecol. Reprod. Biol.20071311616710.1016/j.ejogrb.2006.10.013 17113210
     [Google Scholar]
  87. FelembanA. TanS.L. TulandiT. Laparoscopic treatment of polycystic ovaries with insulated needle cautery: A reappraisal.Fertil. Steril.200073226626910.1016/S0015‑0282(99)00534‑8 10685526
     [Google Scholar]
  88. KwonC.Y. ChoI.H. ParkK.S. Therapeutic effects and mechanisms of herbal medicines for treating polycystic ovary syndrome: A review.Front. Pharmacol.202011119210.3389/fphar.2020.01192 32903374
     [Google Scholar]
  89. GoswamiP.K. KhaleA. Natural remedies for polycystic ovarian syndrome (PCOS): A review.Int. J. Pharm. Phytopharm. Res.20121396402
     [Google Scholar]
  90. AbasianZ. RostamzadehA. MohammadiM. HosseiniM. Rafieian-kopaeiM. A review on role of medicinal plants in polycystic ovarian syndrome: Pathophysiology, neuroendocrine signaling, therapeutic status and future prospects.Middle East Fertil. Soc. J.201823425526210.1016/j.mefs.2018.04.005
     [Google Scholar]
  91. MillerL.G. MurrayW.J. Herbal Medicinals: A Clinician’s Guide.London, UKRoutledge1998326
     [Google Scholar]
  92. TilburtJ.C. KaptchukT.J. Bulletin of the World Health Organization86th ed; World Health Organization2008594599
     [Google Scholar]
  93. Anonymous. Zanzibar Traditional and Alternative Medicine Policy, Ministry of Health and Social Welfare in Collaboration with: World Health Organization.2008[(accessed on 15 September 2021)]. Available online: https://www.afro.who.int/publications/zanzibar-traditional-and-alternative-medicine-policy-2008
  94. BenzieI.F. GalorS.W. Herbal Medicine: Biomolecular and Clinical Aspects.Boca Raton, FL, USACRC Press2011710.1201/b10787
     [Google Scholar]
  95. LakshmiJ.N. BabuA.N. KiranS.S.M. NoriL.P. HassanN. AshamesA. BhandareR.R. ShaikA.B. Herbs as a source for the treatment of polycystic ovarian syndrome: A systematic review.BioTech2023121410.3390/biotech12010004 36648830
     [Google Scholar]
  96. WalA. WalP. SaraswatN. WadhwaS. A detailed review on herbal treatments for treatment of PCOS-polycystic ovary syndrome (PCOS).Current Nutraceuticals20212319220210.2174/2665978602666210805092103
     [Google Scholar]
  97. KhandelwalR. NathaniS. An ayurvedic approach to PCOS: Aleading cause of female infertility.Int. J. Ayurveda Res.2016137782
     [Google Scholar]
  98. Healthy living. Saraca asoca bark.Available from: https://healthyliving.natureloc.com/wp-content/uploads/2016/08/Ashoka-Bark4.jpg[Accessed January 12, 2021].
  99. AruljothiR. ThiruthaniM. Review of saraca asoca for uterine tonic in traditional siddha medicine.Int. J. Curr. Res. Chem.Pharm. Sci20196613
     [Google Scholar]
  100. AhmadA. HusainA. MujeebM. KhanS.A. NajmiA.K. SiddiqueN.A. DamanhouriZ.A. AnwarF. A review on therapeutic potential of Nigella sativa: A miracle herb.Asian Pac. J. Trop. Biomed.20133533735210.1016/S2221‑1691(13)60075‑1 23646296
     [Google Scholar]
  101. SheerazM. Rational approach towards the role of kalawnji (Nigella sativa linn) in marz-e- akyas khusyatur rehm (polycysticovarian syndrome): A review.Indo Am. J. Pharm.20188510891096
     [Google Scholar]
  102. NafiuA. AlimiS. BabalolaA. OgunladeA. MuhammadF. AbioyeA. oluwafuyi, A.; Oyewole, L.; Akinola, O.; Olayemi, J.; Amin, A.; Abdulmajeed, W.; Musa, I.; Rahman, M. Anti-androgenic and insulin-sensitizing actions of Nigella sativa oil improve polycystic ovary and associated dyslipidemia and redox disturbances.J. Complem. Med. Res.201910418619910.5455/jcmr.20190613045154
     [Google Scholar]
  103. PachiappanS. MatheswaranS. SaravananP.P. GayathiriM. Medicinal plants for polycystic ovary syndrome: A review of phytomedicine research.Int. J. Curr. Res. Chem. Pharmace. Sci.201752788010.22192/ijcrcps
     [Google Scholar]
  104. KaliaV. JadavA.N. BhuttaniK.K. In vivo effect of Asparagus racemosus on serum gonadotrophin levels in immature female wistar rats. 2nd world congress of BiotechDevision Of Herbal medicine: NBRI: Lucknow200340
     [Google Scholar]
  105. GaitondéB.B. JetmalaniM.H. Antioxytocic action of saponin isolated from Asparagus racemosus Willd (Shatavari) on uterine muscle.Arch. Int. Pharmacodyn. Ther.19691791121129 5348388
     [Google Scholar]
  106. SharmaK. BhatnagarM. Asparagus racemosus (Shatavari): A versatile female tonic.Int. J. Pharm.201123855863
     [Google Scholar]
  107. PandeyA.K. GuptaA. TiwariM. PrasadS. PandeyA.N. YadavP.K. SharmaA. SahuK. AsrafuzzamanS. VengayilD.T. ShrivastavT.G. ChaubeS.K. Impact of stress on female reproductive health disorders: Possible beneficial effects of shatavari (Asparagus racemosus).Biomed. Pharmacother.2018103464910.1016/j.biopha.2018.04.003 29635127
     [Google Scholar]
  108. FahadT. IsmathS. Phytochemical & therapeutic potentials of Murrmakki (Commiphor amyrrha).Indian J. Appl. Res.201889102104
     [Google Scholar]
  109. There’s an EO for that. Treat PCOS naturally using essential oils.Available from: https://www.theresaneoforthat.com/treat-pcos-naturally- using-essential-oils/[Accessed January 5, 2021].
  110. EvansW.C. EvansD. TreaseG.E. A taxonomic approach to the study of medicinal plants and animal derived drugs.Treaseand Evans pharmacognosy, 15th.Edinburgh, New YorkWB Saunders200216
     [Google Scholar]
  111. DukeJ. DukeP.K. CellierJ.L. Duke Handbook of medicinal herbs.Environment & Agriculture, Medicine, Dentistry, Nursing & Allied Health.Boca RatonCRC Press2002189610.1201/9781420040463
     [Google Scholar]
  112. KostovaI. DinchevD. Saponins in tribulusterrestris-chemistry and bioactivity.Phytochem. Rev.200542-311113710.1007/s11101‑005‑2833‑x
     [Google Scholar]
  113. AbadjievaD. KistanovaE. Tribulus terrestris alters the expression of growth differentiation factor 9 and bone morphogenetic protein 15 in rabbit ovaries of mothers and f1 female offspring.PLoS One2016112e015040010.1371/journal.pone.0150400 26928288
     [Google Scholar]
  114. SinghP.P. KrishnaA. Anti-hyperglycaemic activity of tribulusterrestrisfruit extract restores metabolic imbalance in letrozole induced-PCOS mice.Int. J. Pharmacogn. Phytochem201911430431110.25258/phyto.11.4.10
     [Google Scholar]
  115. BelwalT. DevkotaH.P. SinghM.K. SharmaR. St. John’s Wort (Hypericumperforatum), nonvitamin and nonmineral. Nutritional SupplementsAcademic Press201941543210.1016/B978‑0‑12‑812491‑8.00056‑4
     [Google Scholar]
  116. MitsiC. EfthimiouK. Infertility: Psychological-psychopathological consequences and cognitive-behavioural interventions.Psychiatriki2014254293302 25630548
     [Google Scholar]
  117. O’ReillyE. SevignyM. SabarreK.A. PhillipsK.P. Perspectives of complementary and alternative medicine (CAM) practitioners in the support and treatment of infertility.BMC Complement. Altern. Med.201414139410.1186/1472‑6882‑14‑394 25310971
     [Google Scholar]
  118. RayburnW.F. GonzalezC.L. ChristensenH.D. StewartJ.D. Effect of prenatally administered hypericum (St John’s wort) on growth and physical maturation of mouse offspring.Am. J. Obstet. Gynecol.2001184219119510.1067/mob.2001.108339 11174501
     [Google Scholar]
  119. CanningS. WatermanM. OrsiN. AyresJ. SimpsonN. DyeL. The efficacy of Hypericum perforatum (St John’s wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial.CNS Drugs201024320722510.2165/11530120‑000000000‑00000 20155996
     [Google Scholar]
  120. Insulite health PCOS. Herbal remedies for PCOS.Available from: https://pcos.com/herbal-remedies/[Accessed January 3, 2021]
  121. chouhan, B.; Kumawat, R.C.; Kotecha, M.; Ramamurthy, A.; Nathani, S. Triphala: A comprehensive ayurvedic review.Int. J. Res. Ayurveda Pharm.20134461261710.7897/2277‑4343.04433
     [Google Scholar]
  122. SingD.C. DhyaniS. KaurG.A. Critical review on Guggulu [CommiphoraWightii(arn.) bhand. & its miraculous medicinal uses.Int. J. Ayurveda Pharma Res.20153119
     [Google Scholar]
  123. KavithaA. NarendraB.A. KumarS.M. KiranV.S. Evaluation of effect of Commiphora wightii in dehydroepiandrosterone (DHEA) induced polycystic ovary syndrome (PCOS) in rats.PharmaTutor2016414755
     [Google Scholar]
  124. RaniR. MishraS. Phytochemistry of guggul (commiphorawightii): A review.Asian J. Res. Chem201364415426
     [Google Scholar]
  125. NariyalV. SharmaP. Kanchnar (Bauhinia variegata) as a medicinal herb: A systematic review.Int. J. Adv. Res.20175958759110.21474/IJAR01/5364
     [Google Scholar]
  126. Netmeds. Kanchanar Guggulu: This ayurvedic formulation treats hormonal imbalance.Available from: https://www.netmeds.com/health-library/post/kanchanar-guggulu-this-ayurvedicformulation-treats-hormonal-imbalance/ [Accessed December 27, 2020].
  127. SangalA. Role of cinnamon as beneficial antidiabetic food adjunct: A review.Adv. Appl. Sci. Res.201124440450
     [Google Scholar]
  128. VangalapatiM. PrakashS. A review on pharmacological activities and clinical effects of cinnamon species.Res. J. Pharm. Biol. Chem. Sci.201231653663
     [Google Scholar]
  129. KortD.H. LoboR.A. Preliminary evidence that cinnamon improves menstrual cyclicity in women with polycystic ovary syndrome: A randomized controlled trial.Am J Obstet Gynecol20142115E1-487E6http://dx.doi.org/10.1016/j.ajog.2014.05.009
     [Google Scholar]
  130. BorzoeiA. RafrafM. NiromaneshS. FarzadiL. NarimaniF. DoostanF. Effects of cinnamon supplementation on antioxidant status and serum lipids in women with polycystic ovary syndrome.J. Tradit. Complement. Med.20188112813310.1016/j.jtcme.2017.04.008 29322000
     [Google Scholar]
  131. SatapathyS. DasN. BandyopadhyayD. MahapatraS.C. SahuD.S. MedaM. Effect of tulsi (ocimum sanctum linn.) supplementation on metabolic parameters and liver enzymes in young overweight and obese subjects.Indian J. Clin. Biochem.201732335736310.1007/s12291‑016‑0615‑4 28811698
     [Google Scholar]
  132. KhanageS.G. SubhashT.Y. BhaiyyasahebI.R. Herbal drugs for the treatment of polycystic ovary syndrome (PCOS) and its complications.Pharm. Res.201921513 31823112
     [Google Scholar]
  133. DastgheibM. Barati-BoldajiR. BahrampourN. TaheriR. BorgheiM. AmooeeS. Mohammadi-SartangM. WongA. BabajafariS. MazloomiS.M. A comparison of the effects of cinnamon, ginger, and metformin consumption on metabolic health, anthropometric indices, and sexual hormone levels in women with poly cystic ovary syndrome: A randomized double-blinded placebo-controlled clinical trial.Front. Nutr.20229107151510.3389/fnut.2022.1071515 36523331
     [Google Scholar]
  134. EsmaeilinezhadZ. BabajafariS. SohrabiZ. EskandariM.H. AmooeeS. Barati-BoldajiR. Effect of synbiotic pomegranate juice on glycemic, sex hormone profile and anthropometric indices in PCOS: A randomized, triple blind, controlled trial.Nutr. Metab. Cardiovasc. Dis.201929220120810.1016/j.numecd.2018.07.002 30538082
     [Google Scholar]
  135. KumarapeliM. KarunagodaK. PereraP.K. A randomized clinical trial to evaluate the efficacy of Satapushpashatavari powered drugwith Satapushpa-shatavari grita for the management of polycystic ovary syndrome (PCOS).IJPSR20189624942499
     [Google Scholar]
  136. Moini JazaniA. Celery plus Anise versus metformin for the treatment of oligomenorrhea in the polycystic ovary syndrome: a tripleblindrandomized clinical trial.Tabriz University of Medical Sciences, School of Traditional Medicine2018
     [Google Scholar]
  137. BorzoeiA. RafrafM. Asghari-JafarabadiM. Cinnamon improves metabolic factors without detectable effects on adiponectin in women with polycystic ovary syndrome.Asia Pac. J. Clin. Nutr.2018273556563 29737802
     [Google Scholar]
  138. ArentzS. SmithC.A. AbbottJ. FaheyP. CheemaB.S. BensoussanA. Combined lifestyle and herbal medicine in overweight women with polycystic ovary syndrome (PCOS): A randomized controlled trial.Phytother. Res.20173191330134010.1002/ptr.5858 28685911
     [Google Scholar]
  139. LaiL. FlowerA. PrescottP. WingT. MooreM. LewithG. Standardised versus individualised multiherb Chinese herbal medicine for oligomenorrhoea and amenorrhoea in polycystic ovary syndrome: A randomised feasibility and pilot study in the UK.BMJ Open201772e01170910.1136/bmjopen‑2016‑011709 28159846
     [Google Scholar]
  140. MombainiE. JafariradS. HusainD. HaghighizadehM.H. PadfarP. The impact of green tea supplementation on anthropometric indices and inflammatory cytokines in women with polycystic ovary syndrome.Phytother. Res.201731574775410.1002/ptr.5795 28244612
     [Google Scholar]
  141. MirmasoumiG. FazilatiM. ForoozanfardF. VahedpoorZ. MahmoodiS. TaghizadehM. EsfehN.K. MohseniM. KarbassizadehH. AsemiZ. The effects of flaxseed oil omega-3 fatty acids supplementation onmetabolic status of patients with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial.Exp. Clin. Endocrinol. Diabetes20181264222228 29117618
     [Google Scholar]
/content/journals/cnt/10.2174/0126659786282036240503112128
Loading
Nature's Remedy: Exploring Herbal Treatments for Polycystic Ovarian Syndrome
Current Nutraceuticals 5, E230524230248 (2024); https://doi.org/10.2174/0126659786282036240503112128
/content/journals/cnt/10.2174/0126659786282036240503112128
/content/journals/cnt/10.2174/0126659786282036240503112128
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): herbal medicine; hyperandrogenism; insulin resistance; menstrual cycles; pathogenesis; Polycystic ovarian syndrome

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test